Plans to create a £10bn ‘megafund’ that would make it easier for pharmaceutical companies in London and across the country to develop groundbreaking new drugs and treatments is one of a number of options that will be discussed today at a special conference hosted by the Mayor of London’s Office.
The Mayor of London, Boris Johnson believes that a radical new approach to life sciences investment is needed if London and the rest of the country is to maximise the full economic and health benefit of its world-leading research and development base.
Against that backdrop, today’s City Hall event will bring together leading figures in industry, finance and research. They will discuss positioning London as a test bed for innovative new funding models that tackle structural problems within life sciences investment and create a large pool of patient capital that supports long-term drug development and company growth.
Experts from organisations including Lilly, Pfizer, Imperial Innovations, Silicon Valley Bank, European Investment Bank and JP Morgan will explore options. These include the potential to establish a ‘megafund’ of up to £10bn created by a mix of debt and equity finance. Another option up for consideration today is to take advantage of a programme set up jointly by the European Commission and the European Investment Bank that is set to make more than €24 billion available over the next seven years.
The meeting is being hosted by the Mayor’s Office in conjunction with MedCity, launched by the Mayor last year to drive forward life sciences research, development, entrepreneurship and commercialisation. The event is supported by the European Investment Bank, a major European funder of research, development and innovation investment.
The Mayor of London Boris Johnson said: “London is one of the most powerful scientific discovery engines in the world, home to an incredible cornucopia of research, medical and financial pre-eminence. By hosting this conference we hope to harness our role as a global financial centre that will bring more life-saving drugs to market and deliver a huge boost to the economy.”
Eliot Forster, Executive Chair of MedCity, said: “If you compare the UK to other leading life sciences hubs, we are extremely competitive – we have huge innovation, creativity and entrepreneurial drive, and we are increasingly agile in translating exciting research into spin-out companies. Capital is a key ingredient that grows those companies and brings therapies to market, and at the moment we simply don’t have enough of it. If we want to develop another GSK or AstraZeneca, if we want to get a full return on the investment we put into our research base, and if we want better therapies more quickly, this is an issue we have to address.”
The UK’s medical and scientific base is regarded as one of the world’s best, with the London-Oxford-Cambridge ‘golden triangle’ alone home to universities consistently rated in the world top 10 and five out of seven of the UK’s seven Academic Health Sciences Centres.
However, UK companies face particular challenges in accessing finance at certain stages of development, including taking promising late-stage research into clinical development, and for phase III trials and beyond*. It can cost up to £15m to reach phase II clinical trial results and £20m to reach small phase III trial results, and take an average of 10 to 15 years to bring a medicine to market. Drug discovery and development also has a high failure rate, meaning that it is perceived as a riskier prospect for investors compared to other technology sectors.
More large pools of capital to fund opportunities in the sector and more long-term ‘patient’ investment are needed for the UK to develop a crucial tier of mid-sized life sciences companies, which it is currently lacking.
To tackle these challenges and create an environment in which life sciences companies can grow and successfully commercialise the UK’s cutting-edge research, today’s event will explore innovative new funding models for drug discovery and development.
These include establishing ‘megafunds’, potentially in the long run of up to £10bn, created using a mix of debt and equity finance that would be able to invest simultaneously in multiple different drugs at different stages of development. By pooling various drug development projects in a single investment portfolio, the overall risk would be lower, with a much higher chance of bringing a minority of successful projects to fruition, which would more than compensate for the potential failure of the remainder. This model is well known in the financial services sector, and one focus of today’s event will be to tackle the key differences in scale and complexity of life science.
A ‘megafund’ could bring together investors who would not normally invest in biomedical research and drug development. In return they could have a small percentage of the royalties from successful products or licensing revenues that result.
Another option would be to make use of the new InnovFin financing and advisory programme set up jointly by the European Commission and the European Investment Bank. The initiative helps to share best practice between innovation and life science focused companies seeking to attract public and private investment in life sciences. It is expected that InnovFin will provide more than £17 billion of new financing for research and innovation across Europe in the next five years.
Jonathan Taylor, European Investment Bank Vice President said: “Across Europe the European Investment Bank supports investment by innovation, life science and pharmaceutical companies of all sizes as well as backing efforts to discover new treatments, such as a vaccine for Ebola. In the UK the EIB is backing investment by world-leading universities and firms such as Imperial Innovations in London and the IP Group to develop innovative products and techniques. By reducing the risk for other investors the EIB can help to catalyse engagement from other sources of finance. Our support for innovation and investment to strengthen European competitiveness is also expected to increase once the €315 billion European Fund for Strategic Investment’s is fully operational. Companies considering innovation investment should get in touch with the EIB to see if we can provide financial or best-practice support through our advisory services in any way.”
Cathrin Petty, Head of EMEA Healthcare Investment Banking at JP Morgan, said: “The UK has world-leading technology and research capability, and MedCity is putting in place the infrastructure and resources to encourage investment into these new companies that are being created. The convergence of this should attract the necessary investment to create the next generation of life sciences companies in the UK, just have we have seen in the tech sector. There is also the opportunity to bring together these tech and life sciences disciplines and create truly disruptive health companies. This investment could be of great significance to the UK economy over the next decade.”
Dr. Belen Carrillo-Rivas, Head R&D Innovation Projects, Worldwide Research and Development, Pfizer said: “Rare disease research is at a critical inflection point in the UK; given that the scientific and technical expertise exists in the UK potentially to make major breakthroughs in understanding the molecular basis of rare diseases. We hope that discussions such as these that the Mayor’s office is hosting can help support scientific advances. We look forward to a future where the UK continues to contribute to the development of innovative medicines and sees patients benefitting from the next generation of transformative therapeutics which are so urgently needed.”
Dr. Tim Luker, Director of External Innovation, Eli Lilly and Company Ltd said: “Lilly welcomes City Hall’s ambition to put London at the forefront of biomedical research, investment and funding. Lilly is a global company with a commitment to innovation and over 60 years research investment in the UK. We believe that only though research collaboration and new funding models can we speed the discovery of new medicines to treat the world’s most challenging medical conditions.”
Nooman Haque, Director of UK Life Sciences & Healthcare, Silicon Valley Bank, said, "Silicon Valley Bank provides life science companies of all stages with innovative financing tools that complement traditional venture capital and public finance. With a fully dedicated UK team and access to a global network of professionals, we are working alongside leading UK life science companies and their investors to provide them with financial solutions that support their ambitions to bring much-needed therapies to the market."
Additional options for incentivising a more patient approach to investment being considered include tax incentives for investors who hold onto shares for more than 10 years, to encourage them to behave more like owners and grow larger companies, and capital gains incentives where lower capital gains tax is paid the longer it takes to get a return.
Notes to Editors
*About clinical trials
All clinical trials of new medicines go through a series of phases to test safety and efficacy:
- Phase I – the first time a new medicine is used in humans, usually healthy volunteers, testing safety in a small number of people, initially in small doses
- Phase II – the medicine is trialled in a larger group of people with the targeted illness
- Phase III – if the medicine has shown efficacy and safety in the first two stages, it is tested in larger groups of ill people and compared against an existing treatment or placebo. This stage can last longer than a year and involve thousands of patients
Established by the Mayor of London with the capital’s three Academic Health Science Centres - Imperial College Academic Health Centre, King’s Health Partners, and UCL Partners - MedCity is a unique collaboration that brings together the outstanding life sciences strengths of London and the greater south east.
Over the next 20 years, MedCity will position the region as a world-leading, interconnected hub for research, development, manufacturing and commercialisation by championing collaboration and entrepreneurship, promoting a joined up and globally distinct life sciences offer, and providing a visible ‘go-to’ point for industry and investors.